Maa: Yhdysvallat
Kieli: englanti
Lähde: NLM (National Library of Medicine)
GLIMEPIRIDE (UNII: 6KY687524K) (GLIMEPIRIDE - UNII:6KY687524K)
MedVantx, Inc.
GLIMEPIRIDE
GLIMEPIRIDE 2 mg
ORAL
PRESCRIPTION DRUG
Glimepiride tablets USP are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see Clinical Studies (14.1) ]. Glimepiride tablets USP should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings. Glimepiride tablets are contraindicated in patients with a history of a hypersensitivity reaction to: - Glimepiride tablets or any of the product’s ingredients [see Warnings and Precautions (5.2) ]. Sulfonamide derivatives: Patients who have developed an allergic reaction to sulfonamide derivatives may develop an allergic reaction to glimepiride tablets. Do not use glimepiride tablets in patients who have a history of an allergic reaction to sulfonamide derivatives. Reported hypersensitivity reactions include cutaneous eruptions with or without pruritus as well as more serious reactions (e.g., anaphylaxis, angioedema, Stevens-Johnson syndrome, dyspnea) [see Warnings and Precauti
Glimepiride tablets USP are available as: 1 mg - mottled pink, round tablet, bisected on both sides. One side of the tablet is debossed with “9” on one side of score and “3” on the other. The other side of the tablet is debossed with “72” on one side of score and “54” on the other. Available in bottles of 100 and 1000. 2 mg - mottled green, round tablet, bisected on both sides. One side of the tablet is debossed with “9” on one side of score and “3” on the other. The other side of the tablet is debossed with “72” on one side of score and “55” on the other. Available in bottles of 100 and 1000. 4 mg - mottled light blue, round tablet, bisected on both sides. One side of the tablet is debossed with “9” on one side of score and “3” on the other. The other side of the tablet is debossed with “72” on one side of score and “56” on the other. Available in bottles of 100, 250, and 1000. Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).
Abbreviated New Drug Application
GLIMEPIRIDE- GLIMEPIRIDE TABLET MEDVANTX, INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE GLIMEPIRIDE TABLETS USP SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR GLIMEPIRIDE TABLETS USP. GLIMEPIRIDE TABLETS USP FOR ORAL USE INITIAL U.S. APPROVAL: 1995 INDICATIONS AND USAGE Glimepiride tablets USP are a sulfonylurea indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (1.1). Important Limitations of Use: Not for treating type 1 diabetes mellitus or diabetic ketoacidosis (1.1). DOSAGE AND ADMINISTRATION Recommended starting dose is 1 or 2 mg once daily. Increase in 1 or 2 mg increments no more frequently than every 1 to 2 weeks based on glycemic response. Maximum recommended dose is 8 mg once daily (2.1). Administer with breakfast or first meal of the day (2.1). Use 1 mg starting dose and titrate slowly in patients at increased risk for hypoglycemia (e.g., elderly, patients with renal impairment) (2.1). DOSAGE FORMS AND STRENGTHS Tablets (scored): 1 mg, 2 mg, 4 mg (3) CONTRAINDICATIONS Hypersensitivity to glimepiride tablets or any of the product’s ingredients (4) Hypersensitivity to sulfonamide derivatives (4) WARNINGS AND PRECAUTIONS Hypoglycemia: May be severe. Ensure proper patient selection, dosing, and instructions, particularly in at-risk populations (e.g., elderly, renally impaired) and when used with other anti-diabetic medications (5.1). Hypersensitivity Reactions: Postmarketing reports include anaphylaxis, angioedema and Stevens-Johnson syndrome. Promptly discontinue glimepiride, assess for other causes, institute appropriate monitoring and treatment, and initiate alternative treatment for diabetes (5.2). Hemolytic Anemia: Can occur if glucose 6-phosphate dehydrogenase (G6PD) deficient. Consider a non-sulfonylurea alternative. (5.3). Potential Increased Risk of Cardiovascular Mortality with Sulfonylureas: Inform patient of risks, benefits and treatment alterna Lue koko asiakirja